Findings

What do systematic reviews say?

4,734 questions · 15,288 findings · 893 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3,864 · 25.3%GRADE not reported 2,222 · 14.5%Very low 3,868 · 25.3%Low 3,280 · 21.5%Moderate 1,676 · 11%High 378 · 2.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Intervention not reported

Serum creatinine at 1 year · adults with renal vasculitis

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 156 participants
Low

Rituximab vs cyclophosphamide

Serious adverse events · adults with renal vasculitis

Rituximab showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.11 [0.72, 1.71]
2 studies · 241 participants
Moderate

Rituximab vs cyclophosphamide

Serious infections · adults with renal vasculitis

Rituximab showed no clear difference in serious Infections compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 0.89 [0.62, 1.92]
2 studies · 241 participants
Moderate

Mycophenolate mofetil vs cyclophosphamide

Death at 6 months · adults with renal vasculitis

Mycophenolate mofetil showed no clear difference in death at 6 months compared with cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.25 [0.35, 4.46]
1 study · 140 participants
Low

Mycophenolate mofetil vs cyclophosphamide

Kidney function · adults with renal vasculitis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mycophenolate mofetil vs cyclophosphamide

Dialysis · adults with renal vasculitis

Mycophenolate mofetil showed no clear difference in dialysis compared with cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1 [0.14, 6.9]
1 study · 140 participants
Low

Mycophenolate mofetil vs cyclophosphamide

Relapse · adults with renal vasculitis

Mycophenolate mofetil showed no clear difference in relapse at any time point compared with cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.8 [1, 3.22]
1 study · 127 participants
Low

Mycophenolate mofetil vs cyclophosphamide

Remission · adults with renal vasculitis

Mycophenolate mofetil probably leads to higher remission at 6 months compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.17 [1.01, 1.35]
3 studies · 216 participants
Moderate

Mycophenolate mofetil vs cyclophosphamide

Serious adverse events · adults with renal vasculitis

Mycophenolate mofetil may leads to higher serious adverse events compared with cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.25
1 study · 140 participants
Low

Mycophenolate mofetil vs cyclophosphamide

Infection · adults with renal vasculitis

Mycophenolate mofetil showed no clear difference in infection compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.27 [0.75, 2.16]
3 studies · 216 participants
Moderate

IVIg vs placebo

Death · adults with renal vasculitis

Intravenous immunoglobulin showed no clear difference in death compared with placebo (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 0.2 [0.01, 3.88]
1 study · 34 participants
Low

Intervention not reported

Dialysis at one year · adults with renal vasculitis

The intervention may leads to lower dialysis at one year (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 0.45 [0.29, 0.72]
6 studies · 235 participants
Low

IVIg vs placebo

Kidney function · adults with renal vasculitis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IVIg vs placebo

Dialysis · adults with renal vasculitis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IVIg vs placebo

Response at 3 months · adults with renal vasculitis

Intravenous immunoglobulin may leads to higher response at 3 months compared with placebo (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 2.33 [1.18, 4.61]
1 study · 34 participants
Low

IVIg vs placebo

Relapse at 3 months · adults with renal vasculitis

Intravenous immunoglobulin showed no clear difference in relapse at 3 months compared with placebo (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.17 [0.39, 3.56]
1 study · 34 participants
Low

IVIg vs placebo

Adverse events · adults with renal vasculitis

Intravenous immunoglobulin may leads to higher adverse events compared with placebo (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 3
1 study · 34 participants
Low

IVIg vs placebo

Serious infection · adults with renal vasculitis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Azathioprine vs cyclophosphamide

Death (all causes) · adults with renal vasculitis for maintenance therapy

Azathioprine showed no clear difference in death (median compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 0.77 [0.35, 1.72]
1 study · 144 participants
Moderate

Azathioprine vs cyclophosphamide

Kidney function · adults with renal vasculitis for maintenance therapy

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found